Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint
Program Halt Seen As 'Hit' To Vaccine-Making Reputation
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
You may also be interested in...
Merck/Ridgeback’s ribonucleoside analog shows nearly 50% reduction of risk for hospitalization or death in Phase III study. Firms will seek EUA in US; a contract is in place for 1.7 million courses of therapy.
After backing off of MRK-7110 for hospitalized patients the company’s focus is on the oral antiviral molnupiravir for outpatients – which would be a huge win, but the drug has yet to fully prove itself in the clinic.
Plus: Sanofi is getting into the mRNA vaccine game under a partnership with Translate Bio but has a lot of catching up to do.